Showing 1111-1120 of 20877 results for "".
- Colonoscopy Screening Lowers Incidence But Not Mortality After 13 Yearshttps://reachmd.com/news/colonoscopy-screening-lowers-incidence-but-not-mortality-after-13-years/2487091/Key Takeaways Invitation to colonoscopy was associated with lower colorectal cancer incidence at 13 years in this randomized population-based comparison. Incidence estimates were stronger in per-protocol analysis and appeared more pronounced for distal
- Orforglipron Maintains Weight Loss After Injectable Therapyhttps://reachmd.com/news/orforglipron-maintains-weight-loss-after-injectable-therapy/2487090/Key Takeaways Greater maintenance of prior weight loss was observed with once-daily oral orforglipron than placebo in both prior-injectable cohorts. All key secondary endpoints were met, including maintenance of at least 80% of the earlier weight reduc
- SYNCHRONIZE-1 Phase III Readout on Survodutidehttps://reachmd.com/news/synchronize-1-phase-iii-readout-on-survodutide/2487079/Key Takeaways Boehringer Ingelheim said survodutide met both co-primary endpoints in SYNCHRONIZE-1 under the efficacy and treatment-regimen estimands. A key secondary endpoint showed a statistically significant reduction in waist circumference versus p
- Stage IV Breast Cancer Incidence and Survival, 2010-2021https://reachmd.com/news/stage-iv-breast-cancer-incidence-and-survival-2010-2021/2487083/Key Takeaways The share of invasive breast cancers diagnosed as stage IV increased modestly from 5.6% in 2010 to 6.0% in 2021. Incidence increases were observed across subtype and demographic strata, although the magnitude varied between groups. <
- SCALE 2026: Ipsen to Present Phase II Corabotase Datahttps://reachmd.com/news/scale-2026-ipsen-to-present-phase-ii-corabotase-data/2487087/Ipsen announced that Phase II data from the LANTIC trial of corabotase will be presented at the SCALE 2026 Symposium on May 16, 2026, in the first aesthetic glabellar lines indication for the investigational molecule. Corabotase is described by Ipsen as a custom-designed recombinant neuroi
- Sefaxersen Phase 2 Trial Signals Proteinuria Reduction in IgA Nephropathyhttps://reachmd.com/news/sefaxersen-phase-2-trial-igan/2487066/Key Takeaways In IgA nephropathy, sefaxersen treatment was associated with lower proteinuria at week 29, while kidney function remained stable. Selective reductions were observed in alternative pathway-related biomarkers, while classical pathway activi
- Short-Term Corticosteroid Use Not Linked to Increased IOP in 3 Trialshttps://reachmd.com/news/short-term-corticosteroid-use-not-linked-to-increased-iop-in-3-trials/2487073/A pooled analysis of 3 randomized clinical trials found no evidence that short-term topical or systemic corticosteroid therapy increases intraocular pressure (IOP), a concern associated with corticosteroid-induced glaucoma. T
- Triple Inhaler Improves Outcomes in Uncontrolled Asthma Trialshttps://reachmd.com/news/triple-inhaler-improves-outcomes-in-uncontrolled-asthma-trials/2487061/Key Takeaways Higher-dose BGF was associated with improved lung function across comparisons and lower severe exacerbation rates versus BFFcombined and BFFS. The studies were multicentre, randomized, double-blind, double-dummy phase 3 trials in patients
- Text-Messaging Program Improves Cardiovascular Risk Behaviors in Psoriasishttps://reachmd.com/news/text-messaging-program-improves-cardiovascular-risk-behaviors-in-psoriasis/2487068/Structured text-messaging interventions were associated with an improvement cardiovascular risk-related behaviors and patient activation in adults with psoriasis, according to new study results published online in JAMA Dermatology.
- Sasanlimab Plus BCG In CREST Improves Event-Free Survivalhttps://reachmd.com/news/sasanlimab-plus-bcg-in-crest-improves-event-free-survival/2487062/Key Takeaways Adding sasanlimab to BCG induction and maintenance was associated with longer investigator-assessed event-free survival than BCG induction and maintenance alone. The induction-only combination arm did not significantly differ from the BCG